1. There is no significant difference in treating advanced gastric cancer refractory to chemotherapy with Paclitaxel or Irinotecan.
Evidence rating level: 1 (Excellent)
Study Rundown: Gastric cancer, though uncommon in the United States, is among the most common cancers diagnosed worldwide. Though the development of chemotherapy with fluoropyrimidine plus platinum has...